GLPG2534

GLPG2534 (2 h) inhibits IRAK4 with IC₅₀ values of 6.4 nM and 3.5 nM for human and mouse IRAK4^[1].
GLPG2534 inhibits IL-1β–driven IL-6 release, with an IC₅₀ of 55 nM^[1].
GLPG2534 inhibits TNF-α–driven IL-6 release with an IC₅₀ of 6.6 μM^[1].
GLPG2534 (0.1-10 μM, 16 h) inhibits expression of S100A7, DEFB4A, CXCL8, TNF in Flagellin-stimulated keratinocytes^[1].

GLPG2534 (0.3-10 mg/kg, p.o.) Inhibits CL097-driven release of TNF-α in blood of mice^[1].
GLPG2534 (10 and 30 mg/kg, p.o., b.i.d. 5 days) attenuates inflammation in psoriasis-like mouse models^[1].
GLPG2534 (3-30 mg/kg, p.o., b.i.d. 5 days) attenuates the development of IL-33- and MC903-induced AD-like skin inflammation in mice^[1].

References:
[1]. Lavazais S, et al. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases. Sci Transl Med. 2023 Feb 15;15(683):eabj3289.